This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cyclerion Therapeutics’s 8K filing here.
Cyclerion Therapeutics Company Profile
Cyclerion Therapeutics, Inc, a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc for the treatment of rare kidney disease.
Further Reading
- Five stocks we like better than Cyclerion Therapeutics
- Best Aerospace Stocks Investing
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- How to Use the MarketBeat Excel Dividend Calculator
- Salesforce’s Clear Path to $400 and Beyond
- What is a Stock Market Index and How Do You Use Them?
- HCA Healthcare: 4 Reasons to Buy the 25% Dip
